Super CAR-T

CAR-T cell therapy targeting glypican-3 (GPC3) · Guangzhou FineImmune Biotechnology Co., LTD.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Super CAR-T, covering 2026-03-25 to 2026-03-25. Get the full timeline:

Most recent: Clinical Trial Update: An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma [Phase 1]

See pricing